Heidelberg Pharma AG
26.10.17 19:55
#1
BICYPAPA
Heidelberg Pharma AG
Diskussions und News Thread zu Heidelberg Pharma AG. In den letzten Tagen wurde die Wilex AG in Heidelberg Pharma AG umbenannt, um so der neuen Ausrichtung der Firma gerecht zu werden.
Webseite: http://www.wilex.de/de/
Die erste wichtige Meldung kommt aber noch aus dem Wilex Erbe. Partner RedHill erhält Orphan Drug-Status für MESUPRON.
http://www.finanznachrichten.de/...atus-fuer-mesupron-deutsch-016.htm
Webseite: http://www.wilex.de/de/
Die erste wichtige Meldung kommt aber noch aus dem Wilex Erbe. Partner RedHill erhält Orphan Drug-Status für MESUPRON.
http://www.finanznachrichten.de/...atus-fuer-mesupron-deutsch-016.htm
2292 Postings ausgeblendet.
19.12.22 10:16
#2294
Mogli3
Zusammenarbeit
Binghamton University Nathan Tumey:
I'm excited to announce that we entered a research collaboration and option agreement with Heidelberg Pharma to develop our TLR agonist ADC platform! We are looking forward to working Andreas Pahl, George Octavian Badescu and the rest of the Heidelberg team to push this technology forward. We believe that there are exciting potential synergies between our TLR platform and Heidelberg's clinical-stage ATAC technology!
I'm excited to announce that we entered a research collaboration and option agreement with Heidelberg Pharma to develop our TLR agonist ADC platform! We are looking forward to working Andreas Pahl, George Octavian Badescu and the rest of the Heidelberg team to push this technology forward. We believe that there are exciting potential synergies between our TLR platform and Heidelberg's clinical-stage ATAC technology!
19.12.22 11:24
#2295
Mausbeer
A2JPD6
Ich finde die Nachricht seitens A2JPD6 (siehe oben) sehr positiv und bin überrascht, dass A2JPD6 sich im Chart so schlecht entwicklet hat. Derzeit stehen wir hier im ATL. ich kann mir das nur insofern erklären, als das die guten Studiendaten einen Ausblick auf Studien phase 3 geben, die extern über eine KE zu finanzieren ist.
19.12.22 12:18
#2297
Mogli3
RedHill und COVID-19
Bei RedHill tut sich wieder mal was bei Upamostat/ RHB-107 ( Lizenz von Heidelberg Pharma). Siehe Seiten 56-59 der Präsentation.
https://s28.q4cdn.com/226515471/files/doc_presentations/2022…
https://s28.q4cdn.com/226515471/files/doc_presentations/2022…
20.12.22 19:53
#2300
Mausbeer
Cohort 4 Dosing Stopped per Clinical Trial Protoco
https://investor.magentatx.com/news-releases/...gta-117-phase-12-dose
21.12.22 09:16
#2301
Guru51
abfall gestern
auf den fußball übertragen:
theo hernandes ( equice tricolore )
spielt einen rückpaß unsauber auf einen mitspieler.
messi hätte den ball erreichen können,
hat er aber nicht.
descamps hat den theo in der pause
sicherlich ziemlich zusammengefaltet.
für das ergebnis des spiels
war der vorgang jedoch bedeutungslos.
theo hernandes ( equice tricolore )
spielt einen rückpaß unsauber auf einen mitspieler.
messi hätte den ball erreichen können,
hat er aber nicht.
descamps hat den theo in der pause
sicherlich ziemlich zusammengefaltet.
für das ergebnis des spiels
war der vorgang jedoch bedeutungslos.
21.12.22 10:56
#2302
NullPlan520
Guru du untertreibst.
Fussballtechnisch war das ein Eigentor!!
Aber das Spiel läuft hier nicht nur 90 Minuten.
Jetzt gilt es den Ball wieder in den eigenen Reihen zu halten.
Erfolge dieser anderer Produkte sollten den Kurs in den nächsten Monaten
wieder positiv bewegen.
Ich persönlich hätte nichts gegen einen weiteren kleinen Kursverfall.
Möchte im Januar noch etwas nachkaufen, am liebsten für 4.98 Euro.
Aber das Spiel läuft hier nicht nur 90 Minuten.
Jetzt gilt es den Ball wieder in den eigenen Reihen zu halten.
Erfolge dieser anderer Produkte sollten den Kurs in den nächsten Monaten
wieder positiv bewegen.
Ich persönlich hätte nichts gegen einen weiteren kleinen Kursverfall.
Möchte im Januar noch etwas nachkaufen, am liebsten für 4.98 Euro.
21.12.22 11:17
#2303
Juliette
Ich empfehle zu dem Thema
den informativen Thread bei w:o. inklusive einer dort jüngst geposteten Rückmeldung der Heidelberg Pharma-IR:
https://www.wallstreet-online.de/diskussion/...rma-ag#neuster_beitrag
https://www.wallstreet-online.de/diskussion/...rma-ag#neuster_beitrag
03.01.23 13:23
#2308
Mogli3
Vorteil HDP
RedHill Announces Publication of Positive Phase 2 Study Results with Once-Daily Oral RHB-107 in Non-Hospitalized COVID-19
January 3, 2023
Download(opens in new window)
TeilenFacebookTwitter
Positive data from a U.S. Phase 2 study of once-daily oral RHB-107 (upamostat) in symptomatic COVID-19 published in the peer-reviewed International Journal of Infectious Diseases
RHB-107 successfully met the primary endpoint of safety and tolerability and delivered promising efficacy results, including faster recovery from severe COVID-19 symptoms (median of 3 days to recovery vs. 8 days with placebo) and 100% reduction in hospitalization due to COVID-19
RHB-107, a novel, broad-acting, host-directed, once-daily oral antiviral, is expected to act independently of viral spike protein mutations including Omicron BA.5 sub-variant [1]
Inclusion of once-daily oral RHB-107 in a multinational platform trial for COVID-19 outpatients pending. Discussions for external non-dilutive funding for additional Phase 3 COVID-19 development advancing
Several collaborative projects, with government and non-government bodies, on a range of preclinical studies against other viral targets for pandemic preparedness ongoing and under discussion
TEL AVIV, Israel and RALEIGH, NC, Jan. 3, 2023 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced publication of positive data from a Phase 2 study of once-daily oral investigational RHB-107 (upamostat)[2] in non-hospitalized symptomatic COVID-19 patients, in the peer-reviewed International Journal of Infectious Diseases[3]. The study showed that RHB-107 successfully met the primary endpoint of safety and tolerability and delivered promising efficacy results, despite the small number of patients in each treatment group, including faster recovery from severe COVID-19 symptoms and 100% reduction in hospitalization due to COVID-19.
RedHill Biopharma Ltd. Logo
Data showed a 100% reduction in hospitalization due to COVID-19, with zero patients (0/41) on the RHB-107 arms versus 15% (3/20) hospitalized on the placebo-controlled arm (nominal p-value=0.0317). The study also showed an approx. 88% reduction in reported new severe COVID-19 symptoms after treatment initiation, with only 2.4% of the RHB-107 treated group (1/41) versus 20% (4/20) of patients in the placebo-controlled arm (nominal p-value=0.036) reporting new severe COVID-19 symptoms. Further analysis showed faster recovery from severe COVID-19 symptoms with a median of 3 days to recovery with upamostat vs. 8 days with placebo.
"It is highly satisfying to see this study, and the exciting results it produced, published in this important journal. These data, achieved despite a small overall sample size, are impressive. Showing both safety and efficacy signals, in a highly convenient once-daily oral therapy, positively positions investigational RHB-107 as a potentially very useful treatment for COVID-19 outpatients to reduce symptom severity and prevent disease progression and hospitalization," said Terry F. Plasse MD, Medical Director at RedHill. "Given the growing awareness of the limitations of existing options for early treatment of COVID-19, it is vital that we do not stop our efforts to bring new options forward – especially those in which we have already observed broad-acting, host-directed variant-agnostic abilities."
The Phase 2 multicenter, randomized, double-blind, placebo-controlled, parallel-group study with once-daily oral RHB-107 in non-hospitalized patients with symptomatic COVID-19 (NCT04723537) evaluated safety and tolerability, provided evidence for dose selection, and provided preliminary assessment of parameters to be used for efficacy evaluation in a Phase 3 study. A total of 61 patients were enrolled and randomized on a 1:1:1 basis to receive one of two dose levels of RHB-107 or a placebo control.
Advanced discussions are ongoing regarding inclusion of once-daily oral RHB-107 in a multinational platform trial for COVID-19 outpatients. Discussions for external non-dilutive funding for Phase 3 COVID-19 development, in addition to the platform study, are also advancing.
January 3, 2023
Download(opens in new window)
TeilenFacebookTwitter
Positive data from a U.S. Phase 2 study of once-daily oral RHB-107 (upamostat) in symptomatic COVID-19 published in the peer-reviewed International Journal of Infectious Diseases
RHB-107 successfully met the primary endpoint of safety and tolerability and delivered promising efficacy results, including faster recovery from severe COVID-19 symptoms (median of 3 days to recovery vs. 8 days with placebo) and 100% reduction in hospitalization due to COVID-19
RHB-107, a novel, broad-acting, host-directed, once-daily oral antiviral, is expected to act independently of viral spike protein mutations including Omicron BA.5 sub-variant [1]
Inclusion of once-daily oral RHB-107 in a multinational platform trial for COVID-19 outpatients pending. Discussions for external non-dilutive funding for additional Phase 3 COVID-19 development advancing
Several collaborative projects, with government and non-government bodies, on a range of preclinical studies against other viral targets for pandemic preparedness ongoing and under discussion
TEL AVIV, Israel and RALEIGH, NC, Jan. 3, 2023 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced publication of positive data from a Phase 2 study of once-daily oral investigational RHB-107 (upamostat)[2] in non-hospitalized symptomatic COVID-19 patients, in the peer-reviewed International Journal of Infectious Diseases[3]. The study showed that RHB-107 successfully met the primary endpoint of safety and tolerability and delivered promising efficacy results, despite the small number of patients in each treatment group, including faster recovery from severe COVID-19 symptoms and 100% reduction in hospitalization due to COVID-19.
RedHill Biopharma Ltd. Logo
Data showed a 100% reduction in hospitalization due to COVID-19, with zero patients (0/41) on the RHB-107 arms versus 15% (3/20) hospitalized on the placebo-controlled arm (nominal p-value=0.0317). The study also showed an approx. 88% reduction in reported new severe COVID-19 symptoms after treatment initiation, with only 2.4% of the RHB-107 treated group (1/41) versus 20% (4/20) of patients in the placebo-controlled arm (nominal p-value=0.036) reporting new severe COVID-19 symptoms. Further analysis showed faster recovery from severe COVID-19 symptoms with a median of 3 days to recovery with upamostat vs. 8 days with placebo.
"It is highly satisfying to see this study, and the exciting results it produced, published in this important journal. These data, achieved despite a small overall sample size, are impressive. Showing both safety and efficacy signals, in a highly convenient once-daily oral therapy, positively positions investigational RHB-107 as a potentially very useful treatment for COVID-19 outpatients to reduce symptom severity and prevent disease progression and hospitalization," said Terry F. Plasse MD, Medical Director at RedHill. "Given the growing awareness of the limitations of existing options for early treatment of COVID-19, it is vital that we do not stop our efforts to bring new options forward – especially those in which we have already observed broad-acting, host-directed variant-agnostic abilities."
The Phase 2 multicenter, randomized, double-blind, placebo-controlled, parallel-group study with once-daily oral RHB-107 in non-hospitalized patients with symptomatic COVID-19 (NCT04723537) evaluated safety and tolerability, provided evidence for dose selection, and provided preliminary assessment of parameters to be used for efficacy evaluation in a Phase 3 study. A total of 61 patients were enrolled and randomized on a 1:1:1 basis to receive one of two dose levels of RHB-107 or a placebo control.
Advanced discussions are ongoing regarding inclusion of once-daily oral RHB-107 in a multinational platform trial for COVID-19 outpatients. Discussions for external non-dilutive funding for Phase 3 COVID-19 development, in addition to the platform study, are also advancing.
03.01.23 15:47
#2311
Mogli3
Link Journal
Link zum Journal pre-reviewed Artikel
Klingt vielversprechend
https://doi.org/10.1016/j.ijid.2022.12.003
Klingt vielversprechend
https://doi.org/10.1016/j.ijid.2022.12.003
07.01.23 09:53
#2312
Guru51
cureVac
veröffentlichte diese woche:
".... gab heute positive vorläufige daten aus laufenden klinischen
phase 1-programmen für covid-19 und für die saisonale grippe bekannt. "
curevac hat aktuell eine marktkapitalisierung von ca. 1, 4 mrd euro.
( 187 mio aktien x 7,70 euro )
ladenburg hat aktuell eine MK von 240 mio euro.
( 46,6 mio aktien x 5,06 euro )
kann man / soll man das verstehen ??
".... gab heute positive vorläufige daten aus laufenden klinischen
phase 1-programmen für covid-19 und für die saisonale grippe bekannt. "
curevac hat aktuell eine marktkapitalisierung von ca. 1, 4 mrd euro.
( 187 mio aktien x 7,70 euro )
ladenburg hat aktuell eine MK von 240 mio euro.
( 46,6 mio aktien x 5,06 euro )
kann man / soll man das verstehen ??
24.01.23 15:15
#2316
Mogli3
Interview
Interview im Effektenspiegel mit dem CEO Jan Schmidt-Brand. Er geht von einer Zulassung bei Tlx250 noch in 2023 aus.
https://bit.ly/3kF6Xtq
https://bit.ly/3kF6Xtq
25.01.23 13:17
#2318
Mogli3
Null
Das ist bei Biotechfirmen im Forschungsstadium nun mal so und HDP ist mit ihren Kandidaten erst am Anfang. Außer den alten auslizenzierten Wirkstoffen wie der an Telix. Das bringt Cash ab 2024, bis daraus alle Aufwendungen finanziert werden können wird es aber dauern.